Resources

Science & Documentation

Technical documentation, peer-reviewed research and industry references supporting AlgaeCo's ingredient platform and the broader case for marine microalgae.

Featured Research

Start Here

Illustrative image for cardiovascular research feature Karola G / Pexels
Cardiovascular

JELIS Trial — Pure EPA Reduces Coronary Events by 19%

The Lancet · 2007

In statin-treated patients with elevated cholesterol (n=18,645), daily pure EPA supplementation at 1.8 g/day reduced major coronary events by 19% over a 4.6-year follow-up.

Read the study →
Smiling man with skincare cream applied to forehead and cheeks August de Richelieu / Pexels
Skin Health

Zeaxanthin Shown to Protect Skin from UV-Induced Damage in Clinical Trial

Skin Pharmacol Physiol · 2007

A double-blind, placebo-controlled clinical study of zeaxanthin (combined with lutein) measured five skin parameters — hydration, elasticity, surface lipids, photoprotective activity and lipid peroxidation. Oral and topical administration both showed significant antioxidant benefits, with the combination giving the highest protection against UV-induced skin damage.

Read the study →
Runner on a tree-lined road in early morning light Quang Nguyen Vinh / Pexels
Performance

12 Weeks of Omega-3 Improves Running Economy and VO₂ Peak

Med Sci Sports Exerc · 2023

A randomised controlled trial of 26 amateur long-distance runners — 12 weeks of EPA + DHA significantly improved running economy and VO₂ peak versus placebo.

Read the study →
EPA & Cardiovascular Health

Clinical Evidence for EPA Omega-3

Clinical Trial

JELIS — EPA Reduces Coronary Events by 19% in 18,645 Patients

The Japan EPA Lipid Intervention Study, published in The Lancet, was a large-scale randomised trial of 1.8 g/day pure EPA added to statin therapy vs statin alone in 18,645 hypercholesterolaemic patients. EPA supplementation produced a 19% reduction in major coronary events over 4.6 years — and a 53% reduction in the highest-risk subgroup.

Yokoyama et al. · The Lancet · 2007
Read →
Eye & Vision Health

Macular Pigments and Long-Term Vision

Landmark RCT · 2013

AREDS2 — Lutein + Zeaxanthin and Omega-3s in Age-Related Macular Degeneration

A randomised clinical trial (n=4,203) examining lutein, zeaxanthin and omega-3 supplementation in patients at risk of progression to advanced AMD. Lutein/zeaxanthin showed beneficial effects on AMD progression in defined subgroups. Published in JAMA.

Chew et al. · JAMA · 2013
Read →
Long-Term Follow-Up · 2022

AREDS2 Report 28 — 10-Year Outcomes of Lutein/Zeaxanthin and ω-3 in AMD

A 10-year follow-up of the AREDS2 cohort confirming the long-term benefit of lutein and zeaxanthin in slowing progression to advanced AMD. Published in JAMA Ophthalmology.

Chew et al. · JAMA Ophthalmology · 2022
Read →
Skin Health

Carotenoids and Skin Protection

RCT · 2007

Combined Oral/Topical Lutein and Zeaxanthin — Effects on Human Skin

A double-blind, placebo-controlled clinical study measuring five skin parameters (hydration, elasticity, surface lipids, photoprotective activity, lipid peroxidation) after oral and/or topical lutein + zeaxanthin. Combined oral + topical administration gave the highest antioxidant protection against UV-induced skin damage. Published in Skin Pharmacology and Physiology.

Palombo et al. · Skin Pharmacol Physiol · 2007
Read →
RCT · 2016

Oral Lutein and Zeaxanthin Isomers Improve Skin Tone — 12-Week RCT

A 12-week randomised, double-blind, placebo-controlled clinical trial showing that oral supplementation with lutein and zeaxanthin isomers improved overall skin tone and skin-lightening parameters, with proposed mechanisms including blue-light filtering, antioxidant activity and modulation of melanin pathways. Published in Clinical, Cosmetic and Investigational Dermatology.

Juturu et al. · Clin Cosmet Investig Dermatol · 2016
Read →
RCT · 2020

Oral Mixed Carotenoids Protect Skin Against UVA-Induced Pigmentation

A 12-week randomised, double-blind, placebo-controlled clinical trial (n=60) of an oral mixed-carotenoid supplement containing β-carotene, α-carotene, lutein and zeaxanthin. Significant increases in minimal persistent pigmentation dose (MPPD) at 8 and 12 weeks indicated improved skin protection against UVA radiation. Published in Photodermatology, Photoimmunology & Photomedicine.

Baswan et al. · Photodermatol Photoimmunol Photomed · 2020
Read →
Systematic Review · 2025

Oral Supplements and Photoprotection — Systematic Review of 47 Human Studies

A systematic review of 47 human studies assessing dietary supplements for photoprotection. The authors found the strongest evidence of UV protection for polyphenols, Polypodium leucotomos and carotenoid-based supplements (including lutein and zeaxanthin). Published in the Journal of Medicinal Food.

Natarelli et al. · Journal of Medicinal Food · 2025
Read →
Nannochloropsis oceanica

The Science Behind Our Species

Peer-Reviewed · 2025

EPA Production in Nannochloropsis oceanica Under Industrial Outdoor Conditions

Published 2025 in Processes (MDPI). Research into EPA productivity of N. oceanica in open and closed reactor systems under real-world climate conditions, validating scalability for industrial outdoor cultivation — directly relevant to AlgaeCo's raceway pond approach.

Processes, MDPI · 2025
Read →
Nannochloropsis in Human Studies

Human Clinical Evidence — Nannochloropsis EPA

RCT · 2020

EPA-Rich Nannochloropsis Extract Decreases Cholesterol — 3-Month RCT

A double-blind randomised placebo-controlled trial (n=120) showed 12 weeks of EPA-rich Nannochloropsis extract significantly reduced total and remnant cholesterol and improved the Omega-3 Index. Published in Nutrients.

Rao et al. · Nutrients · 2020
Read →
Real-World Cohort · 2024

Real-World Study — Nannochloropsis EPA Reduces Triglycerides and Cholesterol

A post-market cohort study of over 200 consumers taking 1 g/day EPA-rich Nannochloropsis oil (AlmegaPL®) for six months. The study confirmed and extended the earlier RCT findings, showing a 14.9% reduction in plasma triglycerides and continued cholesterol-lowering effects in a real-world supplement-user population. Published in Frontiers in Nutrition.

Ganuza et al. · Frontiers in Nutrition · 2024
Read →
Performance & Recovery

Omega-3 in Endurance and Recovery

RCT · 2025

EPA-Rich and DHA-Rich Omega-3 Alter Submaximal Exercise Physiology

A six-week randomised trial (n=55) in endurance-trained amateurs compared EPA-rich fish oil, DHA-rich algae oil and placebo. Both omega-3 groups significantly raised the Omega-3 Index, reduced exercising heart rate and lowered rating of perceived exertion versus placebo. Published in Frontiers in Nutrition.

Blannin, Boulton & Thielecke · Frontiers in Nutrition · 2025
Read →
Narrative Review · 2023

Athletes Can Benefit from Increased Intake of EPA and DHA — Evaluating the Evidence

A comprehensive review of EPA and DHA intake in athlete populations, examining mechanisms including the omega-3 index, recovery, inflammation, and performance markers. Published in Nutrients.

Tomczyk et al. · Nutrients · 2023
Read →
Mechanism Review · 2014

Pro-Resolving Lipid Mediators — How EPA Resolves Inflammation

A foundational Nature review describing specialised pro-resolving mediators (SPMs) — resolvins, protectins and maresins — derived from EPA and DHA. Establishes the mechanistic basis for omega-3's role in recovery, joint comfort and resolution of inflammation.

Serhan · Nature · 2014
Read →
Mood & Mental Wellbeing

EPA in Mood and Depression Research

Meta-Analysis · 2016

Meta-Analysis of Omega-3 PUFA Supplementation for Major Depressive Disorder

A meta-analysis of 13 randomised controlled trials (n=1,233) examining omega-3 supplementation in major depressive disorder. The analysis identified formulation factors — particularly EPA-to-DHA ratio and total EPA dose — as key determinants of efficacy. Published in Translational Psychiatry.

Mocking et al. · Translational Psychiatry · 2016
Read →
Meta-Analysis · 2019

Efficacy of Omega-3 PUFAs in Depression — A Meta-Analysis

A meta-analysis confirming that omega-3 PUFA formulations with ≥60% EPA significantly reduce depressive symptoms versus placebo, while DHA-predominant formulations show no such effect. Published in Translational Psychiatry.

Liao et al. · Translational Psychiatry · 2019
Read →
Mechanism · 2020

EPA Increases Anti-Inflammatory and Pro-Resolving Lipid Mediators in Depression

A dose- and time-dependent study showing EPA supplementation in patients with major depressive disorder and chronic inflammation produces measurable increases in circulating SPMs — providing a mechanistic link between EPA, resolution of inflammation and mood outcomes.

Lamon-Fava et al. · Prostaglandins Leukot Essent Fatty Acids · 2020
Read →
Match/Mismatch RCT · 2024

Omega-3 Fatty Acids for Inflamed Depression — A Match/Mismatch Study

A randomised trial examining whether omega-3 supplementation produces stronger antidepressant effects in patients with elevated inflammatory markers — supporting precision-nutrition approaches to depression treatment. Published in Brain, Behavior, and Immunity.

Brain, Behavior, and Immunity · 2024
Read →
Healthy Ageing & Joint Health

Inflammation, Resolution and Mobility

Review · 2012

Omega-3 PUFAs and Inflammatory Processes — Nutrition or Pharmacology?

A comprehensive review of EPA and DHA's role in inflammatory processes, examining mechanisms relevant to joint health, cardiovascular ageing and the body's natural inflammatory balance. Published in the British Journal of Clinical Pharmacology.

Calder · British Journal of Clinical Pharmacology · 2012
Read →
Clinical Review · 2000

n-3 Fatty Acid Supplements in Rheumatoid Arthritis

A review of clinical evidence for omega-3 supplementation in rheumatoid arthritis, summarising randomised trial outcomes on joint tenderness, morning stiffness and NSAID requirements. Published in the American Journal of Clinical Nutrition.

Kremer · American Journal of Clinical Nutrition · 2000
Read →
Composition · 2007

Micro-algae as a Source of Protein

A foundational review of microalgae as a protein source, including essential amino acid profiles of Nannochloropsis and other commercially relevant species — supporting the case for algal biomass in active nutrition and functional food formats.

Becker · Biotechnology Advances · 2007
Read →
Companion Animal Nutrition

Omega-3 and ARA in Pet Health

Veterinary Review · 2015

An Overview of Fatty Acids in Companion Animal Medicine

A clinical overview of dietary fatty acids in dogs and cats, covering EPA, DHA, ARA and their roles in skin and coat condition, joint mobility, and healthy ageing in companion animals. Published in the Journal of the American Veterinary Medical Association.

Lenox et al. · JAVMA · 2015
Read →
Regulatory Reference

AAFCO Nutrient Profiles — Arachidonic Acid Essentiality in Feline Diets

The AAFCO nutrient profile establishes arachidonic acid (ARA) as an essential dietary requirement for cats — a key differentiator for Nannochloropsis-derived ingredients, which naturally contain ARA alongside EPA, unlike conventional fish oil sources.

AAFCO Model Bills & Regulations
Read →
Algal Oil vs Fish Oil

The Case for Going Straight to the Source

Bioavailability · 2025

Comparative Bioavailability of EPA and DHA from Microalgal vs Fish Oil

Published in the International Journal of Molecular Sciences, this study directly compares absorption of EPA and DHA from microalgal and fish oil sources — providing clinical evidence that algal-derived omega-3 delivers equivalent bioavailability to fish oil.

International Journal of Molecular Sciences, MDPI · 2025
Read →
Sustainability Review · 2025

Algal Oils as a Sustainable Source of Essential Omega-3 Fatty Acids

A comprehensive 2025 review in Sustainable Chemistry and Pharmacy examining algal oils as a vegan, eco-friendly alternative for omega-3 production — covering cultivation, extraction, scalability and the environmental case for moving away from fish-derived omega-3.

Sustainable Chemistry and Pharmacy, ScienceDirect · 2025
Read →
Industry & Market

The Industry Is Already Shifting

Industry Report · 2026

Catching the Green Wave — The Future of Omega-3 Sustainability

NutraIngredients reports on the accelerating industry shift from fish oil to microalgae, including dsm-firmenich's 2024 exit from the fish oil business to focus exclusively on algae — and what this means for the omega-3 supply chain going forward.

NutraIngredients · April 2026
Read →
Market Data · 2026

Global Algae Oil Market — USD 3.76 Billion by 2036

Future Market Insights' latest analysis confirms the global algae oil market at USD 2.52 billion in 2025, growing at 3.7% CAGR to reach USD 3.76 billion by 2036 — driven by plant-based omega-3 demand, nutraceutical expansion and the shift away from fish-derived ingredients.

Future Market Insights via Morningstar · April 2026
Read →

Need Technical Documentation?

Spec sheets, COAs and supporting documentation available on request from our team.

Contact Us →